Excellence in Cancer Care Award Archives

🏛️Early Academic Pursuits

Lina Wang completed her Bachelor’s degree at Taishan Medical University (2004-2010), followed by a Master’s degree from Peking Union Medical College (2010-2013). She further pursued her Ph.D. in Medicine at Shanghai Jiao Tong University School of Medicine (2013-2017). With an unrelenting drive for excellence, she completed a postdoctoral fellowship at the University of Maryland School of Medicine (2018-2020), where she deepened her understanding of oncological research and built a strong foundation for her future studies.

Since July 2017, Lina Wang has been serving as an Associate Professor at the Affiliated Hospital of Jining Medical University. Her professional journey has been marked by significant strides in cancer research, particularly focusing on lung cancer, esophageal cancer, and leukemia. She is committed to advancing cancer diagnosis, treatment, and prognosis through rigorous scientific investigation. Her postdoctoral research at the University of Maryland significantly enhanced her expertise in molecular oncology.

Lina Wang’s research has brought significant advancements in the understanding of cancer pathogenesis, particularly in lung and esophageal cancers. Her work in developing efficient prognostic models based on cuproptosis and disulfidptosis has established her as a leader in the field of cancer biomarkers. She has extensively explored the molecular mechanisms underlying tumor progression and has validated several diagnostic and prognostic biomarkers for lung adenocarcinoma. Notably, her research on the TGF-β1/SH2B3 axis has provided new insights into the regulation of anoikis resistance and epithelial-mesenchymal transition (EMT) in lung cancer cells. Additionally, her earlier studies demonstrated that the deletion of Stk40 impairs definitive erythropoiesis in mouse fetal livers, contributing to the broader understanding of developmental biology.

Lina Wang’s groundbreaking research has not only advanced scientific knowledge but also holds potential to transform clinical practices in cancer diagnosis and treatment. By identifying tumor-associated diagnostic and prognostic markers, her work offers tangible benefits to clinical patients, improving the precision of medical interventions. Her research on the molecular mechanisms driving cancer progression contributes to the development of targeted therapies that can effectively treat aggressive cancers such as lung adenocarcinoma.

Lina Wang’s research efforts have been recognized by the National Natural Science Foundation of China, which awarded her a grant (grant no. 81800182) for her project from 2019 to 2021. This funding has enabled her to push the boundaries of cancer research, supporting her work on diagnostic and prognostic markers, as well as molecular mechanisms in oncology.

Lina Wang’s publications on topics such as cuproptosis and cancer prognosis have been widely cited in scientific literature, reflecting the relevance and influence of her work in the academic community. Her research has contributed to the establishment of new prognostic models, and her findings have been cited in numerous oncology-focused journals, further solidifying her reputation as a key contributor in cancer research.

As Lina Wang continues her academic journey, her future contributions promise to further enhance the understanding of cancer mechanisms and improve treatment strategies. With a focus on the identification of novel biomarkers and therapeutic targets, her work is expected to have a lasting impact on the fields of oncology and personalized medicine. Her ongoing research efforts are set to leave a lasting legacy in the medical community, inspiring future generations of researchers.

Construction of lncRNA Prognostic Model Related to Disulfidptosis in Lung Adenocarcinoma
Authors: Zhang, L., Wang, S., Wang, L.
Journal: Heliyon, 2024, 10(15), e35657
Prognostic Value and Immunological Function of Cuproptosis-Related Genes in Lung Adenocarcinoma
Authors: Zhang, L., Wang, S., Wang, L.
Journal: Heliyon, 2024, 10(9), e30446
LncRNA CALML3-AS1 Modulated by m6A Modification Induces BTNL9 Methylation to Drive Non-Small-Cell Lung Cancer Progression
Authors: Zhang, H., Wang, S.-Q., Zhu, J.-B., Duan, C.-J., Zhang, C.-F.
Journal: Cancer Gene Therapy, 2023, 30(12), pp. 1649–1662
Research Progress on Ferroptosis in Lung Cancer
Authors: Dong, Z., Wang, L., Zhang, L., Hu, R.
Journal: Journal of Chinese Physician, 2023, 25(11), pp. 1754–1757
Alterations of Gut Microbiota and Gut Metabolites in the Young-Adult Vitiligo Patients
Authors: Wu, Q., Cheng, P., Shao, T., Yao, S., Lu, B.
Journal: Journal of the European Academy of Dermatology and Venereology, 2023, 37(7), pp. e904–e907